ABSTRACT

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children and adolescents and its main symptoms are attention deficit, hyperactivity and impulsivity. Atomoxetine is a selective noradrenaline reuptake inhibitor with proven efficacy in the treatment of ADHD. Although it is known that it has side effects such as gastrointestinal problems, sleep problems, irritability and fatigue, atomoxetine is frequently preferred in children and adolescents with ADHD who also have tic disorder. However, a small number of patients whose tics started or worsened during atomoxetine treatment have been reported. In this case report, we discussed the mechanism of this adverse effect in a 7-year-old child who used atomoxetine for ADHD treatment who had treatment related triggering of tics.

Keywords: ADHD, atomoxetine, tic

REFERENCES

1Felt BT, Biermann B, Christner JG, Kochhar P, Harrison RV. Diagnosis and management of ADHD in children. Am Fam Physician. 2014;90:456-464.

2Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48:209-225.

3Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11:251-265.

4Yang R, Li R, Gao W, Zhao Z. Tic Symptoms Induced by Atomoxetine in Treatment of ADHD: A Case Report and Literature Review. J Dev Behav Pediatr. 2017;38:151-154.

5Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.

6Tate RL, Perdices M, Rosenkoetter U, Shadish W, Vohra S, Barlow DH, Horner R, Kazdin A, Kratochwill T, McDonald S, Sampson M, Shamseer L, Togher L, Albin R, Backman C, Douglas J, Evans JJ, Gast D, Manolov R, Mitchell G, Nickels L, Nikles J, Ownsworth T, Rose M, Schmid CH, Wilson B. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement. Evid Based Commun Assess Interv. 2016;10:44-58.

7Cothros N, Medina A, Pringsheim T. Current pharmacotherapy for tic disorders. Expert Opin Pharmacother. 2020;21:567-580.

8Lee TS, Lee TD, Lombroso PJ, King RA. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry. 2004;43:1068-1069.

9Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003;13:53-63.

10Ogundele MO, Ayyash HF. Review of the evidence for the management of co-morbid Tic disorders in children and adolescents with attention deficit hyperactivity disorder. World J Clin Pediatr. 2018;7:36-42.

11Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11:251-265.

12Comings DE, Comings BG. Tourette’s syndrome and attention deficit disorder with hyperactivity: are they genetically related? J Am Acad Child Psychiatry. 1984;23:138-146.

Atomoxetine Induced Tics in ADHD Treatment: A Case Report

ABSTRACT

REFERENCES